154 related articles for article (PubMed ID: 35243242)
1. The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia.
Xu Y; Fang H; Chen Y; Tang Y; Sun H; Kong Z; Yang F; Kirschner-Schwabe R; Zhu L; Toker A; Xiao N; Zhou BS; Li H
iScience; 2022 Mar; 25(3):103881. PubMed ID: 35243242
[TBL] [Abstract][Full Text] [Related]
2. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
3. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
4. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
5. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
6. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
7. Downregulating Notch counteracts Kras
Kong G; You X; Wen Z; Chang YI; Qian S; Ranheim EA; Letson C; Zhang X; Zhou Y; Liu Y; Rajagopalan A; Zhang J; Stieglitz E; Loh M; Hofmann I; Yang D; Zhong X; Padron E; Zhou L; Pear WS; Zhang J
Leukemia; 2019 Mar; 33(3):671-685. PubMed ID: 30206308
[TBL] [Abstract][Full Text] [Related]
8. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
9. Mutation-Specific and Common Phosphotyrosine Signatures of
Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
[No Abstract] [Full Text] [Related]
10.
Chang YI; Kong G; Ranheim EA; Tu PS; Yu YS; Zhang J
Am J Transl Res; 2017; 9(3):1326-1334. PubMed ID: 28386358
[TBL] [Abstract][Full Text] [Related]
11. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
[TBL] [Abstract][Full Text] [Related]
12. Loss of Heterozygosity for
Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
[TBL] [Abstract][Full Text] [Related]
13. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
Kerr EM; Gaude E; Turrell FK; Frezza C; Martins CP
Nature; 2016 Mar; 531(7592):110-3. PubMed ID: 26909577
[TBL] [Abstract][Full Text] [Related]
14. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of a small-molecule inhibitor of KRAS
Vázquez-Borrego MC; Granados-Rodríguez M; Bura FI; Martínez-López A; Rufián-Andújar B; Valenzuela-Molina F; Rodríguez-Ortiz L; Haro-Yuste S; Moreno-Serrano A; Ortega-Salas R; Pineda-Reyes R; Michán C; Alhama J; Romero-Ruiz A; Arjona-Sánchez Á
Exp Hematol Oncol; 2023 Dec; 12(1):102. PubMed ID: 38066554
[TBL] [Abstract][Full Text] [Related]
16. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X; Zhang R; Yao J; Mu B; Zhao C
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
[TBL] [Abstract][Full Text] [Related]
17. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
[TBL] [Abstract][Full Text] [Related]
18. ETS1 regulates Twist1 transcription in a Kras
Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
[TBL] [Abstract][Full Text] [Related]
19. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]